Align Technology ALGN
- Market cap
- $11B
- PE
- 26.9×
- 10y median 43.3×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.7×
- EV/EBIT
- 16.2×
- Revenue, 12 months
- $4.1B
- +4% on a year ago
- Net margin
- 10.0%
- Free cash flow yield
- 5.8%
Align Technology trades at 26.9× trailing earnings, cheaper than 86% of the last ten years. Revenue was $4.1B over the last twelve months, up 4% on a year earlier with a 10% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $960.2M+8% | $956.7M+6% | $997.4M+6% | $1B+3% | $977.9M+2% | $995.2M+4% | $979.3M−2% | $1B−2% | $995.7M+2% | $1B+5% | $1B+6% | $1.1B+4% | |
| Cost of revenue | $297.1M+10% | $287.2M+1% | $299.6M+6% | $305.9M+6% | $296.1M−0% | $298.3M+4% | $299.2M−0% | $304.3M−1% | $356.5M+20% | $364M+22% | $303.5M+2% | $298.8M−2% |
| Gross profit | $663.1M+7% | $669.5M+8% | $697.8M+6% | $722.6M+1% | $681.8M+3% | $696.9M+4% | $680.1M−3% | $708.1M−2% | $639.2M−6% | $683.6M−2% | $736.6M+8% | $757.4M+7% |
| R&D | $88.7M+15% | $82.2M−2% | $91.9M+5% | $92.2M+4% | $85.3M−4% | $94.9M+16% | $97.2M+6% | $96.4M+5% | $93.3M+9% | $83M−13% | $98.7M+2% | $102M+6% |
| SG&A | $408M+2% | $402.5M−2% | $451.8M+3% | $452.3M−0% | $434.1M+6% | $425M+6% | $447.6M−1% | $448.7M−1% | $417.8M−4% | $441.7M+4% | $465.3M+4% | $462.7M+3% |
| $166.3M+16% | $171.5M+52% | $154.1M+15% | $147M−15% | $162.3M−2% | $144.1M−16% | $131.1M−15% | $163M+11% | $96.3M−41% | $155.3M+8% | $142M+8% | $154M−6% | |
| Pre-tax income | $162.1M+32% | $172.9M+50% | $158.4M+18% | $143.9M−16% | $165.9M+2% | $140.8M−19% | $140.4M−11% | $173.5M+21% | $94.7M−43% | $176.6M+25% | $148.9M+6% | $148.7M−14% |
| $40.7M−19% | $48.9M−34% | $53.4M+14% | $47.3M−21% | $50M+23% | $37M−24% | $47.2M−12% | $48.9M+3% | $38M−24% | $40.8M+11% | $36.1M−24% | $40.4M−17% | |
| Net income | $121.4M+67% | $124M+197% | $105M+20% | $96.6M−14% | $116M−5% | $103.8M−16% | $93.2M−11% | $124.6M+29% | $56.8M−51% | $135.8M+31% | $112.8M+21% | $108.3M−13% |
| $1.58+70% | $1.64+204% | $1.39+22% | $1.28−12% | $1.55−2% | $1.39−15% | $1.27−9% | $1.72+34% | $0.78−50% | $1.89+36% | $1.57+24% | $1.51−12% | |
| 76.8M−2% | 75.7M−3% | 75.3M−2% | 75.2M−2% | 74.8M−3% | 74.5M−2% | 73.6M−2% | 72.6M−4% | 72.4M−3% | 71.7M−4% | 71.6M−3% | 71.5M−2% |
EPS, diluted: 17 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 17 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Align Technology's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ALGNAlign Technology | $11B | 26.9× | 43.3× | 2.7× | +4% | 10.0% | |
| GMEDGlobus Medical | $10.9B | 20.8× | 37.4× | 3.5× | +20% | 17.0% | |
| COOCooper Companies | $11.6B | 20.9× | 40.2× | 2.7× | +5% | 13.5% | |
| PODDInsulet | $10.3B | 27.9× | 63.0× | 3.4× | +29% | 12.3% | |
| PENPenumbra | $12.8B | 79.7× | 197× | 8.5× | +18% | 10.7% | |
| SOLVSolventum | $14.5B | 10.4× | 10.7× | 1.7× | −1% | 17.3% | |
| MSAMSA Safety | $7B | 22.7× | 36.3× | 3.6× | +6% | 16.1% | |
| MMSIMerit Medical Systems | $5.6B | 38.6× | 57.5× | 3.5× | +10% | 9.2% | |
| HAEHaemonetics | $5.4B | 58.1× | 51.6× | 4.0× | +0% | 7.1% | |
| VNTVontier | $4.6B | 14.3× | 13.5× | 1.5× | +1% | 11.3% | |
| BMIBadger Meter | $4.4B | 35.3× | 47.6× | 5.0× | −2% | 14.3% | |
| Peer median | $8.7B | 25.3× | 43.9× | 3.5× | +6% | 12.9% |
Investors who own it
Investors we follow who held Align Technology at the end of Jun 30, 2026, from their 13F filings.
- Ruane, Cunniff & GoldfarbRuane, Cunniff & Goldfarb (Sequoia Fund)3.1% of portfoliotrimmed
- Cathie WoodARK Investment Management0.0% of portfoliotrimmed
More on Align Technology
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .